Literature DB >> 25588700

R Wave in aVL Lead is a Robust Index of Left Ventricular Hypertrophy: A Cardiac MRI Study.

Pierre-Yves Courand1, Adrien Grandjean2, Paul Charles2, Vinciane Paget3, Fouad Khettab2, Giampiero Bricca4, Loïc Boussel5, Pierre Lantelme1, Brahim Harbaoui1.   

Abstract

BACKGROUND: In patients free from overt cardiac disease, R wave in aVL lead (RaVL) is strongly correlated with left ventricular mass index (LVMI) assessed by transthoracic echocardiography. The aim of the present study was to extend this finding to other settings (cardiomyopathy or conduction disorders), by comparing ECG criteria of left ventricular hypertrophy (LVH) to cardiac MRI (CMR).
METHODS: In 501 patients, CMR and ECG were performed within a median-period of 5 days. CMR LVH cut-offs used were 83 g/m2 in men and 67 g/m2 in women.
RESULTS: RaVL was independently correlated with LVMI in patients with or without myocardial infarction (MI) (N = 300 and N = 201, respectively). SV3 was independently correlated with LVMI and LV enlargement only in patients without MI. In the whole cohort, RaVL had area under receiver-operating characteristic curve of 0.729 (specificity 98.3%, sensitivity 19.6%, optimal cut-off 1.1 mV). The performance of RaVL was remarkable in women, in Caucasians, and in the presence of right bundle branch block. It decreased in case of MI. Overall, it is proposed that below 0.5 mV and above 1.0 mV, RaVL is sufficient to exclude or establish LVH. Between 0.5 and 1 mV, composite indices (Cornell voltage or product) should be used. Using this algorithm allowed classifying appropriately 85% of the patients.
CONCLUSIONS: Our results showed that RaVL is a good index of LVH with a univocal threshold of 1.0 mV in various clinical conditions. SV3 may be combined to RaVL in some conditions, namely LV enlargement to increase its performance. © American Journal of Hypertension, Ltd 2015. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ECG; R wave in aVL lead.; blood pressure; cardiac MRI; hypertension; left ventricular hypertrophy

Mesh:

Year:  2015        PMID: 25588700     DOI: 10.1093/ajh/hpu268

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

1.  Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.

Authors:  Mathilde Berger; Mona Amini-Adlé; Delphine Maucort-Boulch; Philip Robinson; Luc Thomas; Stéphane Dalle; Pierre-Yves Courand
Journal:  Cancer Med       Date:  2020-02-14       Impact factor: 4.452

2.  Electrocardiographic criteria which have the best prognostic significance in hypertensive patients with echocardiographic hypertrophy of left ventricle: 15-year prospective study.

Authors:  Dragan B Djordjevic; Ivan S Tasic; Svetlana T Kostic; Bojana N Stamenkovic; Milan B Lovic; Nikola D Djordjevic; Goran P Koracevic; Dragan B Lovic
Journal:  Clin Cardiol       Date:  2020-06-03       Impact factor: 2.882

3.  Evaluation of the Reliability of Electrocardiographic Criteria for Cardiac Hypertrophy Based on Echocardiographic Data.

Authors:  Agnė Augustaitytė; Eglė Kalinauskienė
Journal:  Acta Med Litu       Date:  2022-07-26

4.  The association between ECG criteria and Echo criteria for left ventricular hypertrophy in a general Chinese population.

Authors:  Tingting Lv; Yifang Yuan; Jing Yang; Guijin Wang; Lingyun Kong; Huijuan Li; Xingjie Li; Yingxian Sun; Xuewen Li; Zheng Zhang; Xiaoshu Cheng; Lirong Wu; Xuerui Tan; Bing Han; Hua Li; Zhaoguo Zhang; Jiayu Wang; Yangfeng Wu; Yanfang Wang; Jihong Guo; Ping Zhang
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-07-26       Impact factor: 1.468

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.